NCT00432939

Brief Summary

This is a research study to investigate cardiovascular health in people with mild hyperparathyroidism. Previous research has suggested that severe hyperparathyroidism may be associated with abnormalities in the heart and blood vessels. It is unclear whether mild hyperparathyroidism affects cardiovascular health. This study involves the investigation of the heart and blood vessels of people with mild hyperparathyroidism. Various non-invasive laboratory and radiological test to assess cardiovascular and bone health will be done at set intervals over the course of 2 years. It is our hypothesis that patients with primary hyperparathyroidism will have subtle abnormalities in their cardiovascular system. Using state-of-the art techniques that are sufficiently sensitive to detect these subtle abnormalities, we will define cardiovascular features of this disease that have, up to now, eluded clear definition. We expect taht the extent of these findings will be related to the severity of the underlying primary hyperparathyroidism. We further hypothesize that cardiovascular manifestations may regress with successful cure of the hyperparathyroid state.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2005

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

February 6, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 8, 2007

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2009

Completed
3.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

March 9, 2015

Status Verified

March 1, 2015

Enrollment Period

4.1 years

First QC Date

February 6, 2007

Last Update Submit

March 6, 2015

Conditions

Keywords

Primary Hyperparathyroidism

Outcome Measures

Primary Outcomes (1)

  • Structural evidence of increased vascular stiffness or cardiovascular calcification in patients with mild asymptomatic PHPT

    To determine whether or not there is structural evidence of increased vascular stiffness or cardiovascular calcification in patients with mild asymptomatic PHPT as compared to matched healthy controls, and to determine the reversibility of these manifestations after successful parathyroidectomy

    2 years

Secondary Outcomes (2)

  • Evidence of abnormal cardiovascular function in patients with mild asymptomatic PHPT

    2 years

  • Evidence of abnormal cardiovascular structure or function in patients with asymptomatic PHPT who meet NIH Guidelines for Surgery

    2 years

Other Outcomes (1)

  • To determine the association between the severity of PHPT and the presence of altered cardiovascular structure and function

    2 years

Eligibility Criteria

Age50 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults age 50 to 75 with Primary Hyperparathyroidism

You may qualify if:

  • Primary Hyperparathyroidism

You may not qualify if:

  • Current use of oral bisphosphonates
  • Addition or change in cholesterol lowering medication
  • impaired renal function (creatinine \>2.0 mg/dl)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Metabolic Bone Diseases Unit

New York, New York, 10032, United States

Location

Related Publications (1)

  • Camporese G, Bernardi E, Bortoluzzi C, Noventa F, Hong NV, Callegari E, Villalta S, Tonello C, Nardin M, Campello E, Spiezia L, Simioni P. MAC Project-Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol. Front Med (Lausanne). 2021 Jan 28;7:584459. doi: 10.3389/fmed.2020.584459. eCollection 2020.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Specimens of frozen serum will be retained for possible future analyses.

MeSH Terms

Conditions

Hyperparathyroidism, Primary

Condition Hierarchy (Ancestors)

HyperparathyroidismParathyroid DiseasesEndocrine System Diseases

Study Officials

  • Shonni J Silverberg, MD

    Columbia University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine, Endocrinology

Study Record Dates

First Submitted

February 6, 2007

First Posted

February 8, 2007

Study Start

October 1, 2005

Primary Completion

November 1, 2009

Study Completion

December 1, 2012

Last Updated

March 9, 2015

Record last verified: 2015-03

Locations